Ophthalmic timolol: Plasma concentration and systemic cardiopulmonary effects

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 2, 2007, Pages 237-245

  Nieminen, T ^a   Lehtimaki T ^b   Maenpaa J ^c   Ropo, A ^c   Uusitalo, H ^b   Kahonen M ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Santen Oy   (Finland)

Author keywords

Adverse effects; Cardiovascular; Haemodynamics; Pulmonary

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; METOPROLOL; PROPRANOLOL; TIMOLOL MALEATE;

AQUEOUS SOLUTION; AREA UNDER THE CURVE; ASTHMA; BRADYCARDIA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CARDIOPULMONARY FUNCTION; CARDIOPULMONARY HEMODYNAMICS; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; EXERCISE; FORCED EXPIRATORY VOLUME; GEL; GENE MUTATION; GENETIC VARIABILITY; GLAUCOMA; HEART INDEX; HEART RATE; HEMODYNAMICS; HUMAN; INTRAOCULAR HYPERTENSION; MUSCLE TONE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROTEIN FUNCTION; PULSE WAVE; REVIEW; SIDE EFFECT; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; AMIDES; BLOOD PRESSURE; DRUG DELIVERY SYSTEMS; HEART RATE; HUMANS; HYDROGEL; RESPIRATORY FUNCTION TESTS; TIMOLOL;

EID: 33947146094     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601034736     Document Type: Review

References (43)

1. Ulrych M, Franciosa J, Conway J. Comparison of a new beta adrenergic blocker (MK 950) and propranolol in man. Clin Pharmacol Ther 1972;13:232-8.
2. Brazier DJ, Smith SE. Ocular and cardiovascular response to topical carteolol 2 % and timolol 0.5 % in healthy volunteers. Br J Ophthalmol 1988;72:101-3.
3. Neufeld AH, Bartels SP, Liu JH. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol 1983;28 Suppl:286-92.
4. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84:710-3.
5. Doyle WJ, Weber PA, Meeks RH. Effect of topical timolol maleate on exercise performance. Arch Ophthalmol 1984;102:1517-8.
6. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986;104:197-9.
7. Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol 1996;121:367-71.
8. Vuori ML, Ali-Melkkila T, Kaila T, Iisalo E, Saari KM. Plasma and aqueous humor concentrations and systemic effects of topical betaxolol and timolol in man. Acta Ophthalmol (Copenh) 1993;71:201-6.
9. Nino J, Tahvanainen K, Uusitalo H, Turjanmaa V, Hutri-Kähönen N, Kaila T, et al. Cardiovascular effects of ophthalmic 0.5 % timolol aqueous solution and 0.1 % timolol hydrogel. Clin Physiol Funct Imaging 2002;22:271-8.
10. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5 % timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002;240:430-5.
11. Uusitalo H, Nino J, Tahvanainen K, Turjanmaa V, Ropo A, Tuominen J, et al. Efficacy and systemic side-effects of topical 0.5 % timolol aqueous solution and 0.1 % timolol hydrogel. Acta Ophthalmol Scand 2005;83:723-8.
12. Uusitalo H, Kahonen M, Ropo A, Maenpaa J, Bjarnhall G, Hedenstrom H, et al. Improved systemic safety and risk-benefit ratio of topical 0.1 % timolol hydrogel compared with 0.5 % timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol 2006;244:1491-6.
13. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004;25:193-200.
14. Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S, et al. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 2004;5:779-802.
15. Shedden AH, Laurence J, Barrish A, Olah TV. Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol 2001;103:73-9.
16. Urtti A. Delivery of antiglaucoma drugs: ocular vs systemic absorption. J Ocul Pharmacol 1994;10:349-57.
17. Vuori ML, Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995;233:131-4.
18. Dickstein K, Hapnes R, Aarsland T, Kristianson K, Viksmoen L. Comparison of topical timolol vs betaxolol on cardiopulmonary exercise performance in healthy volunteers. Acta Ophthalmol (Copenh) 1988;66:463-6.
19. Umetsuki MH, Kotegawa T, Nakamura K, Nakano S, Nakatsuka K. Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men. J Clin Pharmacol 1997;37:58-63.
20. Stewart WC, Cate EA, Stewart JA. Systemic beta-blockade with once daily betimol or timoptic-XE. J Ocul Pharmacol Ther 1999;15:225-31.
21. Stewart WC, Stewart JA, Crockett S, Kubilus C, Brown A, Shams N. Comparison of the cardiovascular effects of unoprostone 0.15 %, timolol 0.5 % and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol Scand 2002;80:272-6.
22. Stewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmol Scand 2002;80:277-81.
23. Ohno Y, Iga T, Yamada Y, Nagahara M, Araie M, Takayanagi R. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). Curr Eye Res 2005;30:319-28.
24. Dickstein K, Hapnes R, Aarsland T. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol 2001;132:626-32.
25. Diggory P, Cassels-Brown A, Vail A, Hillman JS. Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol 1998;82:146-9.
26. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol 1999;128:301-9.
27. Takahashi N, Iwasaka T, Sugiura T, Onoyama H, Kurihara S, Inada M, et al. Effect of coenzyme Q10 on hemodynamic response to ocular timolol. J Cardiovasc Pharmacol 1989;14:462-8.
28. Stewart WC, Day DG, Holmes KT, Stewart JA. Effect of timolol 0.5 % gel and solution on pulmonary function in older glaucoma patients. J Glaucoma 2001;10:227-32.
29. Fraunfelder FT, Barker AF. Respiratory effects of timolol. N Engl J Med 1984;311:1441.
30. Wilson TW, Firor WB, Johnson GE, Holmes GI, Tsianco MC, Huber PB, et al. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther 1982;32:676-85.
31. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004;76:536-44.
32. Nieminen T, Uusitalo H, Turjanmaa V, Bjärnhall G, Hedenström H, Maenpää J, et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005;61:369-74.
33. Fourtillan JB, Courtois P, Lefebvre MA, Girault J. Pharmacokinetics of oral timolol studied by mass fragmentography. Eur J Clin Pharmacol 1981;19:193-6.
34. Lohmoller G, Frohlich ED. A comparison of timolol and propranolol in essential hypertension. Am Heart J 1975;89:437-42.
35. Brogden RN, Speight TM, Avery GS. Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension. Drugs 1975;9:164-77.
36. McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin Pharmacol Ther 1985;38:409-13.
37. Lennard MS, Lewis RV, Brawn LA, Tucker GT, Ramsay LE, Jackson PR, et al. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmacol 1989;27:429-34.
38. Huupponen R, Kaila T, Lahdes K, Salminen L, Iisalo E. Systemic absorption of ocular timolol in poor and extensive metabolizers of debrisoquine. J Ocul Pharmacol 1991;7:183-7.
39. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 1995;274:1611-3.
40. Nieminen T, Uusitalo H, Mäenpää J, Turjanmaa V, Rane A, Lundgren S, et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol 2005;61:811-9.
41. Richerson GB. The autonomic nervous system. In: Boron WF, Be L, editors. Medical physiology a cellular and molecular approach: Philadelphia: Saunders99378-98.
42. Hoffman BB, Taylor P. The autonomic and somatic motor nervous systems. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. pp 115-53.
43. Atkins JM, Pugh BR, Jr, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol 1985;99:173-5.